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Accepted 22 April 2013AbstractObjective: To raise awareness among clinicians and epidemiologists that single-patient (n-of-1) trials are potentially useful for inform-
ing personalized treatment decisions for patients with chronic conditions.
Study Design and Setting: We reviewed the clinical and statistical literature on methods and applications of single-patient trials and
then critically evaluated the needs for further methodological developments.
Results: Existing literature reports application of 2,154 single-patient trials in 108 studies for diverse clinical conditions; various recent
commentaries advocate for wider application of such trials in clinical decision making. Preliminary evidence from several recent pilot ac-
ceptability studies suggests that single-patient trials have the potential for widespread acceptance by patients and clinicians as an effective
modality for increasing the therapeutic precision. Bayesian and adaptive statistical methods hold promise for increasing the informational
yield of single-patient trials while reducing participant burden, but are not widely used. Personalized applications of single-patient trials can
be enhanced through further development and application of methodologies on adaptive trial design, stopping rules, network meta-analysis,
washout methods, and methods for communicating trial findings to patients and clinicians.
Conclusions: Single-patient trials may be poised to emerge as an important part of the methodological armamentarium for comparative
effectiveness research and patient-centered outcomes research. By permitting direct estimation of individual treatment effects, they can fa-
cilitate finely graded individualized care, enhance therapeutic precision, improve patient outcomes, and reduce costs.  2013 Elsevier Inc.
All rights reserved.
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1. Introduction deliver an uneven mix of risks and benefits to individual pa-A variety of critiques have been raised on the current
paradigm for producing clinical knowledge. The core criti-
cisms are that: (1) it is practically impossible to conduct
standard parallel-group randomized controlled trials
(RCTs) to address all clinically important questions, even
those restricted to comparative effectiveness of drugs and
devices [1,2]; (2) clinical evidence generated in those RCTs
has poor generalizability and therefore limited applicability
to real patients seen in ordinary practices [3,4]; and (3)
treatments shown to be safe and effective on average mayConflict of interest: The authors have no conflicts of interest related to
the content of this article.
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http://dx.doi.org/10.1016/j.jclinepi.2013.04.006tients, a problem known as heterogeneity of treatment ef-
fects (HTE; [4e10]). Furthermore, practitioners usually
have little leverage over the choice of research topics or
participation in the generation and interpretation of evi-
dence. This represents an important missed opportunity to
facilitate the development of a learning health care system
‘‘to generate and apply the best evidence for the collabora-
tive health care choices of each patient and provider; to
drive the process of discovery as a natural outgrowth of pa-
tient care; and to ensure innovation, quality, safety, and
value in health care’’ [11].
Single-patient trials, also known as n-of-1 trials and
individual-patient trials, have the potential to address these
critiques. Single-patient trials are multiple-period crossover
experiments comparing two or more treatments within indi-
vidual patients. Unlike parallel-group RCTs, single-patient
trials can be used to estimate individual treatment effects
directly. This allows single-patient trials to identify the best
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 Single-patient (n-of-1) trials have struggled to gain
acceptance among researchers, clinicians, and pa-
tients. The comparative effectiveness research
and patient-centered outcomes research move-
ments create an opportunity for such trials to serve
as a clinical decision tool to inform personalized
treatment decisions for patients with chronic
conditions.
 Preliminary evidence from several recent pilot ac-
ceptability studies suggests that single-patient tri-
als may have broader appeal among patients and
clinicians than previously suspected. Bayesian
and adaptive statistical methods hold promise for
increasing the informational yield of single-patient
trials while reducing participant burden, but are not
widely used.
 Personalized applications of single-patient trials
can be enhanced through further development
and application of methodologies on adaptive trial
design, stopping rules, network meta-analysis,
washout methods, and methods for communicating
trial findings to patients and clinicians.treatment for each individual patient [8,12], thereby serving
as a promising clinical decision tool for individual patients
[13] in the spirit of patient-centered outcomes research
(PCOR).
Gabler et al. [14] reviewed single-patient trials reported
in the medical literature during 1985e2010, and identified
100 articles that reported on 108 studies enrolling a total of
2,154 patients. The studies addressed diverse clinical con-
ditions, including neuropsychiatric (36%), musculoskeletal
(21%), and pulmonary (13%). Examples of conditions to
which single-patient trials have been applied successfully
include fibromyalgia, chronic pain, attention-deficit hyper-
activity disorder, insomnia, asthma, chemotherapy-
associated nausea and vomiting, and allergic rhinitis.
The strengths and limitations for single-patient trials are
reviewed in Table 1. To summarize, single-patient trials are
suitable for evaluating long-term treatments for chronic con-
ditions, with stable treatment response, quick onset of treat-
ment effect, and modest or negligible carryover effects. The
presence of HTE renders the evidence for individual treat-
ment effects from single-patient trials especially informative
[8]. Chronicity of the condition and stability of the treatment
response provide opportunities for the initial investment in
a single-patient trial to pay off through improvements in
long-term patient outcomes. The lack of existing evidence
creates a need for the evidence produced in single-patient tri-
als. Slow-onset and/or carryover effects can compromise thevalidity of single-patient trials. Successful single-patient tri-
als need to either ascertain that slow-onset and/or carryover
effects are absent or negligible, or account for these transient
effects with an appropriatewashout period and/or an analytic
strategy to untangle these effects from the true long-term
treatment effect. At the same time, single-patient trials are
not suitable for conditions that are acute or unrelentingly pro-
gressive (e.g., acute leukemia,where the clinician and patient
might have only one chance to get it right); treatments caus-
ing permanent or only slowly reversible effects (e.g., sur-
gery); and preventive treatments targeting conditions
associatedwith uncommon, catastrophic outcomes (e.g., pre-
vention of stroke in atrial fibrillation).
This article discusses how single-patient trials address the
core critiques of evidence-based medicine (including its new
guises, comparative effectiveness research [CER] and PCOR).
We begin by reviewing the methodology of single-patient tri-
als and their potential acceptability as a mainstream clinical
decision tool. We then discuss applying Bayesian methods
to combine single-patient trials across patients to produce es-
timates for individual treatment effects that are more stable
than those generated by individual single-patient trials alone
[15e18]. Finally, we discuss the methodological develop-
ments that could enhance the utility of single-patient trials.2. Overview of methodology
Single-patient trials are multiple-period crossover trials
conducted within individual patients to evaluate the com-
parative effectiveness of two or more treatments for each
specific patient. As the methodology for single-patient tri-
als has been discussed in detail elsewhere [13,15e23], we
provide below only a brief overview. New directions for
single-patient trial methodology are discussed in the
‘‘Methodological developments’’ section below.
We focus on the comparison of two treatments in the rest
of this article; the extension to more than two treatments is
relatively straightforward. Other types of single-subject de-
signs, such as multiple baseline designs commonly used in
social sciences research, differ in key features from single-
patient trials and are not included in this discussion.
The unit of treatment assignment is a prespecified time
period, say 1 week, during which the patient receives either
treatment A or B. The duration of the treatment period is
selected to allow each treatment an adequate time to man-
ifest its effect. Awashout period might be used between the
two treatment periods to eliminate or reduce the carryover
effect of the treatment used in the previous time period.
Treatment assignment is usually randomized and blocked
to ensure good balancewith respect to possible period effects.
For example, within each block of two time periods, both
treatments are used in one time period, so that the treatment
assignments are randomized to either AB or BA in each
block. The number of crossovers is usually prespecified, al-
though some variation is often allowed to accommodate
Table 1. Indications and contraindications for single-patient trials (SPTs)
Feature Description Indication Contraindication
Heterogeneity of treatment
effects (HTE, [8])
Treatment effect varies across patients;
one size does not fit all
With HTE, evidence based on specific patient is
essential to personalize treatment decisions
(e.g., serotonin reuptake inhibitors for
treatment of depression)
Homogeneity of treatment effects (e.g., insulin [titrated to need]
for reduction of blood glucose)
Chronicity Long-term treatment for chronic
condition
Chronicity allows knowledge gleaned from
single-patient trials to inform future treatment
decisions (e.g., gastroesophageal reflux disease)
Acute conditions (e.g., influenza)
One-time treatment with long-lasting effects (e.g., surgery)
Stability Stable treatment effecta Stability ensures that knowledge gleaned from
single-patient trials informs future treatment
decisions
Lack of stability (e.g., in an individual whose dietary intake of
vitamin K fluctuates widely over time, the effects of warfarin
may be unstable relative to the effects of aspirin)
Effect onset and carryover Transition periods between two
treatment periods may be needed
for the effect of previous treatment
to extinguish, and the effect of
new treatment to commence and
stabilize. Insufficient length of
either might confound estimation
of long-term treatment effect
Negligible or modest duration for onset and
carryover (e.g., short-acting psychostimulants
for ADHD) allows single-patient trials to
provide valid knowledge about long-term
treatment effect, especially when accompanied
with appropriate washout or analytic strategies
to untangle slow onset and carryover effects
from long-term treatment effect
Long duration of onset and/or carryover (e.g., long-acting
medications)
Lack of adequate evidence Existing clinical evidence not
adequate to inform treatment
decision for individual patients
Lack of adequate evidence creates the need
for evidence to be gleaned from single-patient
trials (e.g., effectiveness of prophylactic
antibiotics in spinal cord injury patients with
frequent urinary tract infections)
Adequate evidence: there is no need for further evidence from
single-patient trials (e.g., effectiveness of HMG-CoA
reductase inhibitors [statins] for reduction of cardiovascular
risk in individuals with established coronary artery disease)
Abbreviation: ADHD, attention-deficit hyperactivity disorder.
a The assumption of stable treatment effect is weaker than the assumption of stable treatment outcome under both treatments. With the assumption of stable treatment effect, it is possible for
treatment outcome to manifest a time trend, say, a gradual deterioration over time, as long as the trajectories are parallel for the two treatments, so that the difference between the treatments
remains constant (stable). In other words, this assumption amounts to a requirement that treatment effect and time trend are additive, that is, there is no treatment time interaction.
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standard, parallel-group RCTs.
Clinical outcome is assessed repeatedly over time, at
least once within each treatment period. The outcomes ob-
tained during time periods with treatment A are compared
with those obtained during treatment B to determine which
treatment leads to preferred outcomes for the patient.
The analysis of single-patient trials includes informal
evaluations such as visual inspection, simple statistical anal-
ysis such as the paired t-test, time series analysis to account
for possible serial correlation, and Bayesian methods
[13e18,20]. Among the studies reviewed by Gabler et al.
[14], a quarter used visual inspection but no statistical com-
parison; among those that used statistical comparison, 59%
used the t-test, 30% used nonparametric methods, 22% used
regressionmodeling, 32% used pooled analysis, and only 7%
used Bayesian methods (some used multiple methods).
On completion of the single-patient trial and the analy-
sis, the patient and clinician meet to discuss the findings
and decide on the treatment going forward. This decision
must be based on a sound interpretation of the data ob-
tained during the trial, including a careful assessment of
the uncertainty involved that avoids overinterpreting effects
that are driven by random noise in the data.
Single-patient trials primarily seek to produce specific
clinical knowledge for each individual patient to inform
the decision about which treatment to use in the long term.
It is also possible to combine data across individual patients
using Bayesian methods, to improve the clinical decision
for individual patients beyond what can be accomplished
using each patient’s own data alone, and as a byproduct
also to produce aggregate information that can be used to
inform treatment decisions for other patients not participat-
ing in the trials [15e18]. Further discussions of Bayesian
methods are given in the ‘‘Bayesian methods’’ section.3. Acceptability
Several recent commentaries have advocated wider appli-
cation of single-patient trials as a clinical decision tool
[24e28]. Successful implementation, however, depends on
the receptivity of stakeholders who control adoption of this
methodology, especially clinicians and patients. We review
in the following paragraphs several recent pilot acceptability
studies that provide encouraging insights into the appeal of
single-patient trials to these stakeholders.
Brookes et al. [29] conducted a pilot acceptability study
among nine patients with osteoarthritis of the knee partici-
pating in two series of single-patient trials. One series
(n5 5) compared a standard knee support with a heat-
retaining support; the other series (n5 4) compared a
nonsteroidal anti-inflammatory drug, diclofenac, with an
analgesic, paracetamol. Patients were randomized to three
pairs of crossovers, double blinded for the drug trials, and
open label for the knee support trials (cannot blind). Dailydiaries were taken to inform future treatment decisions.
Qualitative, semistructured interviews were conducted with
each patient at the start of the single-patient trial and again
at the completion/termination to solicit patients’ perspec-
tives on trial participation, understanding of the protocol,
initial expectations, and experience of participation. The
authors concluded that the single-patient trial was an ac-
ceptable approach to individualize treatment decisions. Par-
ticipants viewed the single-patient trial as a logical and
accurate method that provided a fair opportunity for them
to experience both treatments. They valued the personal-
ized nature of the trial and its potential to offer improved
treatment.
Kravitz et al. [30] conducted a pilot acceptability study
among clinicians and patients to solicit potential facilitators
and barriers to the adoption of single-patient trials. The study
conducted phone interviews with 21 physicians (9 internal
medicine, 5 family medicine, 4 rheumatology, and 3 pediat-
rics). They conducted focus groups, stratified by age, with 32
adult patients and parents of pediatric patients with at least
one chronic condition. Despite initial lack of familiarity with
the concept of the single-patient trial, both physicians and pa-
tients readily ‘‘grasped the fundamental logic and appreci-
ated the potential benefits’’ of personalizing treatment
decisions and enhancing doctorepatient relationship.
Nikles et al. [31] interviewed 12 Australian stakeholders
recruited using purposive sampling through organizations
considered likely to have an interest in single-patient trials
to provide an optimally broad range of respondent categories
(consumers, doctors, government, and industry). Stake-
holders supported wider implementation of single-patient
trials in a targeted fashion, with some caveats. They recog-
nized the rationale behind single-patient trials to increase
cost-effectiveness of government spending, to improve com-
munity health outcomes, and to maximize the effectiveness
of individual treatment. They also recognized the potential
benefits of single-patient trials, including targeting of ther-
apy, reducing unnecessary prescribing, and reducing health
care costs. Barriers recognized included constraints on doc-
tors’ time, doctors’ acceptance, drug companies’ acceptance,
patient willingness, and cost. The authors identified several
strategies for overcoming these barriers, namely (1) building
single-patient trials into standard clinical consultation, (2)
social marketing, (3) incentives such as payment for nurse
practitioner support, (4) ensuring that the trials are suitable
for real-world conditions and free for patients, (5) restricting
the duration of the trials, and (6) obtaining funding for an in-
dependent organization to conduct the trials.4. Bayesian methods
In most practical applications of single-patient trials, the
number of crossovers that can be conducted is limited by re-
sources and patient burden. Therefore, the comparative ef-
fectiveness estimated from the patient’s own single-patient
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desirable to combine the index patient’s own data with the
data obtained from other patients who participated in similar
single-patient trials to enhance the statistical precision avail-
able for the index patient. Bayesian methods, sometimes
known as borrowing from strength [32], are useful for this
purpose [15e18]. We present in the following paragraphs
an overview of the Bayesian methods. Readers who are not
interested in statistical details are welcome to skip to the
‘‘Methodological developments’’ section.
For a blocked design with two time periods in each block,
the i-th patient’s individual treatment effect (di) can be esti-
matedwithin each block as the difference in the observed out-
come between the two treatments being compared. The
block-specific individual treatment effect estimates can then
be averaged across blocks within the i-th patient to provide
a combined estimate for di. The Bayesian model usually as-
sumes di to be drawn randomly from a normal distribution
with mean d0 denoting the average treatment effect (ATE)
for the population, and standard deviation t denoting the var-
iation in the individual treatment effects across patients (the
HTE). The Bayesian framework requires placing prior distri-
butions on these parameters that represent knowledge about
these parameters before the study, say, from clinical knowl-
edge or previous studies.When prior information is not avail-
able, noninformative prior distributions would be used. The
ATE, d0, and the individual treatment effects, di’s, are then es-
timated using the posterior distribution for each parameter,
usually using the posterior mean or median as the point esti-
mate and the credibility interval based on the posterior distri-
bution as the interval estimate.
The relationship between individual treatment effects and
theATE depends on the balance between the between-patient
and within-patient variances [33]. When between-patient
variance is small compared with the within-patient variance
(i.e., little or no HTE), the individual treatment effects are
very similar and close to the ATE. Alternatively, if between-
patient variance is large compared with the within-patient
variance (i.e., strong HTE), the individual treatment effects
would be estimated to be close to the patient’s observed treat-
ment effect estimate with little or no borrowing from
strength. In this situation, the strength (population informa-
tion) to be borrowed from does not provide strong statistical
information; therefore, the within-patient information domi-
nates the between-patient information.
As a byproduct of the Bayesian method that aims to en-
hance clinical decisions for individual patients, the estimated
ATE and HTE can also be used to inform treatment decisions
for similar patients who did not participate in single-patient
trials.
Some research studies can be designed either as a standard
parallel-group RCT, or as an ensemble of single-patient tri-
als. The parallel group design has more logistical simplicity,
with no need to manage the crossovers and washout. On the
other hand, single-patient trials might deliver greater power/
precision than parallel group designs with the same numberof patients, under the assumption that the carryover effect
is either negligible or controlled for appropriately. With
single-patient trials, the same patient serves as his/her own
control; therefore, the idiosyncrasies unique to each patient
are controlled for automatically. With parallel group designs,
these idiosyncrasies contribute additional uncertainty, result-
ing in lower power/precision.
Related discussions on the precision for single-patient
trials and traditional crossover trials are given in section
2.2.5 and Table 3 in the study of Zucker et al. [18]. They
show that for a study with M patients and N paired-time pe-
riods, study precision is M/(t2þ 2 s2/N ), thus providing
a way to calculate the tradeoff in sample size between the
patients and time periods.5. Methodological developments
As the single-patient trial receives wider attention in the
CER/PCOR framework, further developments in its meth-
odology, as discussed in the following paragraphs, can en-
hance the utility of single-patient trials in clinical practice.
Although awashout periodbetween treatment periods is of-
ten used to guard against carryover effects, this strategy has
limitations. Patients and clinicians might be dissatisfied with
thewithholding of active treatments during thewashout, espe-
cially for comparative effectiveness single-patient trials with
an active control. The lack of active treatments might also re-
sult in suboptimal patient outcomes during the single-patient
trial. Furthermore, washout does not mitigate slow onset of
the new treatment. Rather, the onset is deferred until after
the end of the washout period, stretching the duration of the
transient effects between the two treatment periods.Therefore,
when designing a single-patient trial, there is a need to balance
the benefits ofwashout (such asmitigating the potential bias of
estimated treatment effects) against its limitations.
Hogben and Sim [5,6] used an innovative methodology
to address the carryover effect without a washout period,
taking daily measurements in each 3-day time period, but
downweighting the earlier measures that are more suscepti-
ble to carryover effect. Zucker et al. [17] used a similar ap-
proach by analyzing only a single measurement at the end
of each treatment period. Further analytic strategies can be
used to model outcome trajectories during each treatment
period, to untangle long-term treatment effects from tran-
sient effects owing to carryover of prior treatment and/or
slow onset of new treatment. The ability for analytic strat-
egies to deal with both carryover and slow onset is an im-
portant advantage over the usual strategy of a washout
period. Further development and evaluation of these ana-
lytic methods are warranted.
Further investigation is warranted on effective ways to
summarize findings from each single-patient trial for presen-
tation to the patient and clinician. As there is diversity in the
design and analysis for single-patient trials, there is also di-
versity in the decision process, in particular, how the findings
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sual inspection) used in the existing single-patient trial liter-
ature might be ineffective and vulnerable to overinterpreting
the data when the observed treatment effect might be driven
largely by random noise in the data.
As a patient-centered methodology, single-patient trials
should prioritize incorporating user (patient and clinician)
preferences, both in the design and analysis of the trial,
and in the decision phase. A key consideration is the quan-
titative sophistication of the users. Some users might prefer
to base their treatment decisions on the estimated treatment
effect size and associated confidence interval for each out-
come of interest. Others might prefer to know the posterior
probability or odds for how the two treatments compare in
terms of achieving prespecified goals, such as reducing the
level of pain to a specific level, which takes uncertainty into
consideration. However, such advanced feedback that rec-
ognizes the level of uncertainty in the information may
be too difficult for many to grasp. Graphical presentations
that show the trajectories of treatment responses over time
for the two treatments are probably informative and com-
prehensible to all. Some patients may just prefer the pic-
tures and may rely on their clinician to interpret the data.
Thus, the single-patient trial needs to train patient and cli-
nician to optimize the decision-making process while ac-
commodating user preferences and maintaining scientific
rigor.
Most single-patient trials are focused on prespecified treat-
ments, such as two specific drugs to be compared. Although
this highly structured design facilitates the implementation
and interpretation of the trials (such as Bayesian methods for
combining trial data across patients), a more flexible frame-
workmight be desirable in clinical applications, allowing each
patient and their provider to choose the specific treatments of
particular interest to them. With a flexible framework, it is
more challenging to combine data across patients for the sake
of borrowing from strength. A possible remedy is the use of
networkmeta-analysis [34], to integrate direct (using trials that
compared the specific treatments, say,Avs. B, directly) and in-
direct comparisons (using trials that compared A vs. B indi-
rectly, say, through trials that compared A vs. C and trials
that compared C vs. B), to maximize information available
for the specific comparison of interest.
Essentially all single-patient trials are designed with
a fixed 1:1 randomization ratio with a prespecified number
of time periods. Alternatively, a response-adaptive design
such as the play-the-winner design [35,36] could be used
to allow the randomization ratio to adapt to the interim data
obtained, so as to minimize patient exposure to the inferior
treatment. The application of response-adaptive designs to
single-patient trials calls for new methodological develop-
ment in the multilevel framework (time periods nested
within patients) to incorporate interim data from the index
patient themselves and additional data from other similar
patients. In applying a play-the-winner design, trial experi-
ence from other similar patients can be informative, butinterim data from the index patient themselves should be
weighted more heavily as being more directly relevant.
The common practice of prespecifying the number of
crossovers might not always accommodate the needs of
individual patients [20]. A more flexible strategy not pre-
specifying the number of crossovers can help accommo-
date the HTE across patients, for example, a sequential
stopping rule [37] can be used to terminate the single-
patient trial when a prespecified level of acceptable
uncertainty has been reached. For patients who manifest
dramatic differences between the two treatments, early
stopping is indicated. For example, in a study by Guyatt
et al. [19], a decision was made to terminate the trial after
four time periods (two pairs of crossovers) because the
unblinded data already convinced the patient and the cli-
nician that one of the treatments was superior. Some pa-
tients might prefer more flexibility to allow for early
termination when appropriate. Some might prefer the
simplicity of a standard design with a fixed number of
crossovers. Some patients’ responses might fluctuate sub-
stantially, suggesting the need for more crossovers. Some
patients might generate more consistent results and could
benefit from early termination. Further research on adap-
tive trial design [38] and sequential stopping rules [37] for
application to single-patient trials may facilitate individu-
alization of the single-patient trial to enhance its scientific
validity and user acceptability.6. Summary and conclusions
After several decades of wandering in the wilderness
[12], single-patient trials may be poised to emerge as an im-
portant part of the CER and PCOR methodological arma-
mentarium. These trials render a number of benefits in
clinical care. By permitting direct estimation of individual
treatment effects, they can facilitate finely graded individu-
alized care, enhance therapeutic precision, improve patient
outcomes, and avoid unnecessary costs. New applications
of Bayesian, adaptive, and sequential statistical methods
hold promise for increasing the informational yield of single-
patient trials while reducing participant burden.
Single-patient trials can deliver benefits that extend be-
yond patients participating in the trials. The aggregation
of trial findings through Bayesian methods can inform
treatment decisions for patients unaffiliated with the trials.
In addition, by linking scientific methods to chronic disease
management, single-patient trials encourage clinicians and
patients to actively participate in real clinical learning com-
munities. Supported by the right system-level infrastruc-
ture, clinicians can use single-patient trials to generate
data that are not only scientifically valid but also immedi-
ately available and directly relevant to their patients. In this
way, clinicians can obtain early, actionable feedback on
their practices. It is therefore conceivable that single-patient
trials might serve as a vehicle to facilitate the
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care systems [11].
The way forward is not free of obstacles. Participation in
single-patient trials requires time and effort, and although
some patients and clinicians will be enthusiastic to partici-
pate, others will not be. The application of single-patient
trials is restricted to chronic and symptomatic conditions
with stable treatment outcomes. There is an ongoing ten-
sion among precision (longer trials are better), convenience
(shorter are better), and clinical applicability (when a trial
is too long, the results of earlier periods may no longer ap-
ply if the patient’s condition has evolved).
Preliminary evidence from several recent pilot accept-
ability studies suggests that single-patient trials may be
widely acceptable to patients and clinicians as an effective
modality for increasing therapeutic precision. Because
single-patient trials are akin to informal therapeutic trial-
and-error procedures commonly used in clinical practice,
clinicians may be amenable to upgrade their practice to in-
corporate this formal scientific procedure if the necessary
infrastructure support is available. Even if just a small pro-
portion of patients participate, the absolute number of eligi-
ble patients with chronic conditions who could benefit might
be very large, making way for a prominent role for single-
patient trials in clinical research and practice. If single-
patient trials can succeed in luring only a fraction of eligible
clinicians and patients into the scientific enterprise, the op-
portunity for transforming care through creation of high-
functioning knowledge organizations is immense.Acknowledgments
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